Stock SYRS SYROS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Real-time Estimate Cboe BZX
Other stock markets
 03:55:28 2024-04-19 pm EDT 		5-day change 1st Jan Change
4.56 USD -3.39% Intraday chart for Syros Pharmaceuticals, Inc. -16.88% -42.49%
Apr. 09 Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
Apr. 09 Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise MT

Evolution of the average Target Price on Syros Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5c4879501119eb114016.M0Bb5EREY6o31FmLsXTqmnmiFbv8oW9fN7cAY3qW0BY.B3MWqSMnDIdi7BW73SWTzE_tYe2X8zoOY_lGNzLDnUd0AgOLBwpVzn2mKg~17696dd3b24733ff12e0c379dc539806

Analyst Recommendations on Syros Pharmaceuticals, Inc.

JMP Securities Adjusts Price Target on Syros Pharmaceuticals to $15 From $16, Maintains Market Outperform Rating MT
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $13 From $15, Maintains Outperform Rating MT
Piper Sandler Cuts Price Target on Syros Pharmaceuticals to $20 From $27, Reiterates Overweight Rating MT
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $15 From $30, Maintains Outperform Rating MT
JMP Securities Cuts Price Target on Syros Pharmaceuticals to $16 From $40, Maintains Market Outperform Rating MT
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $3 From $9, Maintains Outperform Rating MT
HC Wainwright Adjusts Price Target on Syros Pharmaceuticals to $6 From $10, Reiterates Buy Rating MT
HC Wainwright Adjusts Price Target on Syros Pharmaceuticals to $10 From $15, Reiterates Buy Rating MT
Alliance Global Adjusts Price Target on Syros Pharmaceuticals to $10 From $14, Reiterates Buy Rating MT
SYROS PHARMACEUTICALS : Roth Capital Adjusts Price Target on Syros Pharmaceuticals to $23 From $20, Maintains Buy Rating MT
SYROS PHARMACEUTICALS : Oppenheimer Adjusts Syros Pharmaceuticals PT to $9 From $13, Maintains Outperform Rating MT
SYROS PHARMACEUTICALS : Wedbush Adjusts Syros Pharmaceuticals' Price Target to $8 From $10, Maintains Neutral Rating MT
SYROS PHARMACEUTICALS : HC Wainwright Upgrades Syros Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $15 From $11 MT
Syros Pharmaceuticals Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.72 USD
Average target price
19.25 USD
Spread / Average Target
+307.84%
High Price Target
37 USD
Spread / Highest target
+683.90%
Low Price Target
12 USD
Spread / Lowest Target
+154.24%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Syros Pharmaceuticals, Inc.

JMP Securities
Oppenheimer
Piper Sandler
HC Wainwright
Alliance Global Partners
Roth Capital Partners

Ratings for Syros Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SYRS Stock
  4. Consensus Syros Pharmaceuticals, Inc.